EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV)

The decision to start the rolling review of this investigational mRNA vaccine is based on preliminary results from laboratory studies and early clinical studies in adults. The Agency will evaluate data from ongoing clinical trials as they become available.

Source:

European Medicines Agency